Cargando…

Antiviral efficacy of favipiravir against canine distemper virus infection in vitro

BACKGROUND: Canine distemper (CD) is an acute infectious disease with high morbidity rates caused by a highly contagious pathogen (Canine Morbillivirus, also known as canine distemper virus, CDV). CDV can infect a broad range of carnivores resulting in complex clinical signs. Currently, there is no...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Xianghong, Zhu, Yelei, Yan, Lina, Wong, Gary, Sun, Peilu, Zheng, Xuexing, Xia, Xianzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720089/
https://www.ncbi.nlm.nih.gov/pubmed/31477101
http://dx.doi.org/10.1186/s12917-019-2057-8
_version_ 1783448049709744128
author Xue, Xianghong
Zhu, Yelei
Yan, Lina
Wong, Gary
Sun, Peilu
Zheng, Xuexing
Xia, Xianzhu
author_facet Xue, Xianghong
Zhu, Yelei
Yan, Lina
Wong, Gary
Sun, Peilu
Zheng, Xuexing
Xia, Xianzhu
author_sort Xue, Xianghong
collection PubMed
description BACKGROUND: Canine distemper (CD) is an acute infectious disease with high morbidity rates caused by a highly contagious pathogen (Canine Morbillivirus, also known as canine distemper virus, CDV). CDV can infect a broad range of carnivores resulting in complex clinical signs. Currently, there is no effective method to treat for CDV infections. Favipiravir (T-705), a pyrazine derivative, was shown to be an effective antiviral drug against RNA viruses, acting on RNA-dependent RNA polymerase (RdRp). However, whether the T-705 has antiviral effects following CDV infection is unclear. Here, we investigated the antiviral effect of T-705 against CDV-3 and CDV-11 strains in Vero and DH82 cell lines. RESULTS: Our data demonstrated that T-705 significantly inhibited the replication of CDV-3 and CDV-11 in both Vero and DH82 cells at different concentrations, ranging from 2.441 μg/ml to 1250 μg/ml. Additionally, T-705 exhibited efficacious antiviral effects when administered at different time points after virus infection. Cytotoxicity tests showed a slight decline in viability in Vero cells after T-705 treatment, and no apparent cytotoxicity was detected in T-705 treated DH82 cells. Comparison of anti-CDV polyclonal serum only inhibition of CDV in supernatant, T-705 directly inhibited viral replication in cells, and indirectly reduced the amount of virions in supernatant. The combination application of T-705 and anti-CDV polyclonal serum exhibited a rapid and robust inhibition against virions in supernatant and virus replication in cells. CONCLUSIONS: Our data strongly indicated that T-705 effectively inhibited viral replication following CDV infection in vitro, and could be a potential candidate for treatment for CD.
format Online
Article
Text
id pubmed-6720089
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67200892019-09-06 Antiviral efficacy of favipiravir against canine distemper virus infection in vitro Xue, Xianghong Zhu, Yelei Yan, Lina Wong, Gary Sun, Peilu Zheng, Xuexing Xia, Xianzhu BMC Vet Res Research Article BACKGROUND: Canine distemper (CD) is an acute infectious disease with high morbidity rates caused by a highly contagious pathogen (Canine Morbillivirus, also known as canine distemper virus, CDV). CDV can infect a broad range of carnivores resulting in complex clinical signs. Currently, there is no effective method to treat for CDV infections. Favipiravir (T-705), a pyrazine derivative, was shown to be an effective antiviral drug against RNA viruses, acting on RNA-dependent RNA polymerase (RdRp). However, whether the T-705 has antiviral effects following CDV infection is unclear. Here, we investigated the antiviral effect of T-705 against CDV-3 and CDV-11 strains in Vero and DH82 cell lines. RESULTS: Our data demonstrated that T-705 significantly inhibited the replication of CDV-3 and CDV-11 in both Vero and DH82 cells at different concentrations, ranging from 2.441 μg/ml to 1250 μg/ml. Additionally, T-705 exhibited efficacious antiviral effects when administered at different time points after virus infection. Cytotoxicity tests showed a slight decline in viability in Vero cells after T-705 treatment, and no apparent cytotoxicity was detected in T-705 treated DH82 cells. Comparison of anti-CDV polyclonal serum only inhibition of CDV in supernatant, T-705 directly inhibited viral replication in cells, and indirectly reduced the amount of virions in supernatant. The combination application of T-705 and anti-CDV polyclonal serum exhibited a rapid and robust inhibition against virions in supernatant and virus replication in cells. CONCLUSIONS: Our data strongly indicated that T-705 effectively inhibited viral replication following CDV infection in vitro, and could be a potential candidate for treatment for CD. BioMed Central 2019-09-02 /pmc/articles/PMC6720089/ /pubmed/31477101 http://dx.doi.org/10.1186/s12917-019-2057-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Xue, Xianghong
Zhu, Yelei
Yan, Lina
Wong, Gary
Sun, Peilu
Zheng, Xuexing
Xia, Xianzhu
Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
title Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
title_full Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
title_fullStr Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
title_full_unstemmed Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
title_short Antiviral efficacy of favipiravir against canine distemper virus infection in vitro
title_sort antiviral efficacy of favipiravir against canine distemper virus infection in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720089/
https://www.ncbi.nlm.nih.gov/pubmed/31477101
http://dx.doi.org/10.1186/s12917-019-2057-8
work_keys_str_mv AT xuexianghong antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro
AT zhuyelei antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro
AT yanlina antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro
AT wonggary antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro
AT sunpeilu antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro
AT zhengxuexing antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro
AT xiaxianzhu antiviralefficacyoffavipiraviragainstcaninedistempervirusinfectioninvitro